Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company that develops new products for treating Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company has two product candidates in development. Alzheimer's disease is a primary focus, which was the seventh leading cause of death in the U.S. in 2021 and 2022. Approximately 7.2 million Americans are currently affected by Alzheimer's, a number projected to increase to 13 million by 2050. Over 11 million Americans provide an estimated 19 billion hours of unpaid care annually for individuals with Alzheimer's. In 2025, the estimated healthcare costs for treating Alzheimer's in the U.S. are expected to be $384 billion, with $246 billion covered by Medicare and Medicaid. These costs could reach $1 trillion per year by 2050 if no permanent treatment or cure is discovered. Existing Alzheimer's treatments offer temporary symptom relief, and while one treatment has shown to slow disease progression, none have been shown to halt it.